Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study.
Cohort Studies
Drug Administration Schedule
Female
Graft Rejection
/ prevention & control
Graft Survival
/ drug effects
Humans
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ administration & dosage
Kidney Transplantation
Male
Middle Aged
Prospective Studies
Tacrolimus
/ administration & dosage
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
09
08
2019
revised:
09
02
2020
accepted:
15
02
2020
pubmed:
19
7
2020
medline:
16
2
2021
entrez:
19
7
2020
Statut:
ppublish
Résumé
Tacrolimus is a cornerstone in the immunosuppressive therapy of kidney transplantation. The once-daily formulation of tacrolimus has been shown to improve adherence of patients without affecting short-term efficacy. However, long-term proof of once-daily tacrolimus efficacy and safety is still lacking. From January 2009 to November 2013, 170 clinically stable kidney transplant patients were offered to change from the ongoing twice-daily tacrolimus (TDT) formulation to a once-daily tacrolimus (ODT) regimen. Kidney transplant recipients agreeing to the change to be treated with an ODT regimen (n = 105, estimated glomerular filtration rate [eGFR] 57.1 ± 1.6 mL/min/1.73 m
Identifiants
pubmed: 32680595
pii: S0041-1345(19)31063-2
doi: 10.1016/j.transproceed.2020.02.149
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3112-3117Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.